Skip to content
2000
Volume 4, Issue 2
  • ISSN: 2210-6847
  • E-ISSN:

Abstract

Myocardial infarction (MI) and heart failure (HF) are leading causes of mortality and morbidity in the Western World. Therapeutic approaches using interventional cardiology and bioengineering techniques have thus far focused on either salvaging viable tissue post-infarction or preserving cardiac function in the failing myocardium. Regenerative medicine on the other hand, attempts to renew damaged tissue and enhance cardiac functional performance. Tremendous advances have been made in this field since the introduction and ethical approval for use of stem-cells (SC) and relevant technologies in pre-clinical and clinical practice. While study outcomes are still ambivalent on the potential translational impact of SCs, renewed hope has arisen since the introduction of induced pluripotent stem-cells (iPS) and the prospect of intact organ development and transplantation. The aim of this work is to review recent discoveries and the patent landscape employing stem-cell engineering, labeling and image-based monitoring strategies, their use in bioreactors and constructions of enriched bio-artificial membranes, as well as the potential role in artificial organ development and transplantation, with relevance to anticipated impact in pre-clinical screening and widespread clinical use.

Loading

Article metrics loading...

/content/journals/rptmi/10.2174/2210684704666140917005858
2014-12-01
2024-11-23
Loading full text...

Full text loading...

/content/journals/rptmi/10.2174/2210684704666140917005858
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test